Adult Patient (Over 18 Yr-old) Admitted to the ICU for Acute PeritonitisPERICANDNCT03469401
Evaluation of BD Glucan in Peritoneal Fluid for the Diagnosis of Fungal Peritonitis
An observational study of Adult Patient (Over 18 Yr-old) Admitted to the ICU for Acute Peritonitis, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
Invasive candidiasis has a high mortality rate, around 40%. Outcome remains tightly linked to the time of treatment administration. Routine microbiological techniques give results too lately to allow prompt antifungal therapy initiation (at least 48 hours). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Adult Patient (Over 18 Yr-old) Admitted to the ICU for Acute Peritonitis
- What is being tested?
- Intervention
- How many people
- 126 participants
- Where
- 1 siteFrance
- Study dates
- 18 Jan 2018to 18 Feb 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis
Who may be able to join
- Aged ≥ 18 years old
- written informed consent for inclusion in the study
- stay in intensive care unit
- diagnosed with a peritonitis
- peritoneal fluid collected by a surgery or radiology procedure, analysed at bacteriology laboratory of l'institut des agents infectieux, l'hôpital de la Croix Rousse
Who cannot join
- Pregnant woman
- Moribund patient
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of the Detection of B D Glucan in Peritonitis Fluid in Intensive Care Unit (ICU) Patients With Peritonitis for the Diagnosis of Fungal Peritonitis, Compared to Routine Microbiology Diagnosis Method. The PERICAND Study
Invasive candidiasis has a high mortality rate, around 40%. Outcome remains tightly linked to the time of treatment administration. Routine microbiological techniques give results too lately to allow prompt antifungal therapy initiation (at least 48 hours). It is important to develop diagnostic tools to initiate antifungal therapy as early as possible.
The B D glucan detection, one of the major components of the candida cell wall, can be useful for a early diagnosis.
Read more
There are several techniques on the market for the detection of glucan. In Europe and America, the most used is Fungitell (Associated of Cape Cod, Inc).
There is several studies about the use of such kits for fungemia. A number of studies are reporting evidences of a early diagnosis.
But, in medical literature, there isn't study focused on the detection of B D glucan in peritoneal fluid for Candida peritonitis diagnosis.
- Being tested
- Intervention
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterventionOther
Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
| Study group | Role | What they receive |
|---|---|---|
| intervention | Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis with a peritoneal fl:uid sample obtained via surgery or radiological drainage Receives: Other: Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2018
- Study start18 Jan 2018
- Primary completion18 Jan 2019
- Study completion18 Feb 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Adult Patient (Over 18 Yr-old) Admitted to the ICU for Acute PeritonitisStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 126 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Florent WALLET, MD, Principal investigator, Hospices Civils de Lyon
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03469401
- Sponsor's protocol ID
- 69HCL17_0775
- Acronym
- PERICAND
- Status last verified
- Aug 2025
- First submitted
- 12 Mar 2018
- Last updated
- 4 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Nourry E, Wallet F, Darien M, Menotti J, Dupont D, Allaouchiche B, Argaud L, Richard JC, Guichon C, Rimmele T, Bohe J, Thiollere F, Vassal O, Lepape A, Wallon M, Persat F, Friggeri A. Use of 1,3-Beta-D-Glucan concentration in peritoneal fluid for the diagnosis of intra-abdominal Candidiasis in Critically-ill patients. Med Mycol. 2023 Mar 20:myad029. doi: 10.1093/mmy/myad029. Online ahead of print.
PubMed 36941133
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Detection of B D Glucan in Peritonitis Fluid in Intensive Care Unit (ICU) Patients With Peritonitis for the Diagnosis of Fungal Peritonitis, Compared to Routine Microbiology Diagnosis Method. The PERICAND Study
- ClinicalTrials.gov ID
- NCT03469401
- Acronym / sponsor ID
- PERICAND / 69HCL17_0775
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 126 participants (actual)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 18 Jan 2018 (actual)
- Primary completion
- 18 Jan 2019 (actual)
- Study completion
- 18 Feb 2019 (actual)
- First posted
- 19 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Invasive candidiasis has a high mortality rate, around 40%. Outcome remains tightly linked to the time of treatment administration. Routine microbiological techniques give results too lately to allow prompt antifungal therapy initiation (at least 48 hours). It is important to develop diagnostic tools to initiate antifungal therapy as early as possible.
The B D glucan detection, one of the major components of the candida cell wall, can be useful for a early diagnosis.
There are several techniques on the market for the detection of glucan. In Europe and America, the most used is Fungitell (Associated of Cape Cod, Inc).
There is several studies about the use of such kits for fungemia. A number of studies are reporting evidences of a early diagnosis.
But, in medical literature, there isn't study focused on the detection of B D glucan in peritoneal fluid for Candida peritonitis diagnosis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| intervention | – | Other: InterventionAdult patient (over 18 yr-old) admitted to the ICU for acute peritonitis with a peritoneal fl:uid sample obtained via surgery or radiological drainage |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis
Key inclusion criteria (5 listed)
- Aged ≥ 18 years old
- written informed consent for inclusion in the study
- stay in intensive care unit
- diagnosed with a peritonitis
- peritoneal fluid collected by a surgery or radiology procedure, analysed at bacteriology laboratory of l'institut des agents infectieux, l'hôpital de la Croix Rousse
Key exclusion criteria (2 listed)
- Pregnant woman
- Moribund patient
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterventionEvaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture | Other | intervention |
Primary outcome
Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
Time frame: 1 year
Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2025.
- Results publication: PubMed 36941133Nourry E, Wallet F, Darien M, Menotti J, Dupont D, Allaouchiche B, Argaud L, Richard JC, Guichon C, Rimmele T, Bohe J, Thiollere F, Vassal O, Lepape A, Wallon M, Persat F, Friggeri A. Use of 1,3-Beta-D-Glucan concentration in peritoneal fluid for the diagnosis of intra-abdominal Candidiasis in Critically-ill patients. Med Mycol. 2023 Mar 20:myad029. doi: 10.1093/mmy/myad029. Online ahead of print.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Florent WALLET, MD principal investigator
Hospices Civils de Lyon
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Adult Patient (Over 18 Yr-old) Admitted to the ICU for Acute Peritonitis, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03469401, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2025.